

FOSUN 复星

A Global Innovation-driven Consumer Group



Disclaimer

It is not the intention of this document to provide a full explanation of any relevant matters of Fosun International Limited (the "Company"). You must refrain from relying on any information set out in this document. No statement, guarantee or undertaking is or will be made or given at present or in the future in respect of the accuracy, fairness, reasonableness, correctness or completeness of this document or any information or opinions set forth herein or any other information or opinions, whether written or oral, available to any stakeholder or its advisers, nor is there or will there be any express or implied indication made in respect of the above content at present or in the future. None of the Company or any of its shareholders, directors, officers, employees, affiliates, advisers or representatives (the "Parties") shall assume any liability, including but not limited to liability for default, for or in respect of the above content at present or in the future. The Parties expressly state that they shall not be held liable for any loss resulting from the use of this document or its content or in any other manner in connection with this document. It is assumed that information set out in this document is appropriate for the current situation and such information could be subject to change without notice. None of the Parties shall be held liable for procuring the receipt of information under this document by any recipients, updating information under this document, or correcting any manifest error contained under this document. In the event of any conflict between this document and the annual results announcement of the Company for the year, and the annual report of the Company for the year ended 31 December 2020 (collectively, the "Annual Documents"), the Annual Documents shall prevail.



FOSUN 复星

About Fosun



* Currency in RMB and data as of 31 December 2020 unless otherwise specified

A Global Innovation-driven Consumer Group¹

Fosun was founded in 1992. Our mission is to provide high-quality products and services for families around the world in health, happiness, wealth and intelligent manufacturing segments.

Revenue

RMB**136.6** billion

41% from overseas

Net Profit

RMB**8.02** billion

8-year CAGR 10%

Total Assets

RMB**767.7** billion

No. of Employees

Approx. **76,000**

Forbes Global Ranking 2021

No. **459**

ESG Rating

A **A**

MSCI

HSI

C-end Customers

470 million

Total customer traffic

358 million

Cumulative registered members



¹ Data as of 31 December 2020

Our Clients: One Billion Families Worldwide

Mission

Creating happier lives for **families** worldwide

Vision

Rooted in China, creating a global happiness ecosystem fulfilling the needs of one billion families in **health, happiness, and wealth**

Value

Self-improvement, Teamwork, Performance, and Contribution to Society



Fosun Family Industrial Ecosystem

Every Stage of life



Marriage



Maternity



Parenting



Midlife



Silver Age

Health

FOSUN PHARMA
复星医药

sisram
medical

FOSUN HEALTH
复星健康

佛山复星禅诚医院
Foshan Fosun Chancheng Hospital

复星星堡
FOSUN STARCASTLE

FOSUN Kite
复星凯特生物

babytree
宝宝树

薄荷健康™

复星杏脉
FOSUN AITROX

Henlius
上海复宏汉霖生物技术股份有限公司

FOSUN DIAGNOSTICS
复星诊断

Happiness

百合网
baihe.com

LANVIN
PARIS

老庙

ATLANTIS
SANYA
三亚·亚特兰蒂斯

sergio rossi



金徽
金徽酒 正能量

世纪佳缘
jiayuan.com

DIJULA
TOAILLERIE / PARIS

AHAVA
ELEMENTAL BEAUTY FROM THE DEAD SEA

SEA-GULL
海鸟表

Thomas Cook
托迈酷客

Club Med
全球度假村，一价享精彩

Wealth

FIDELIDADE
SEGUROS DESDE 1908

HAUCK & AUFHAUSER
PRIVATBANK SEIT 1796



BFC
THE BUND
FINANCE CENTER
|外|滩|金|融|中|心|

FOSUN CAPITAL
复星创富

复星锐正
FOSUN RZ CAPITAL

Millennium
bcp

Intelligent Manufacturing

JEVE
捷威动力

M
海南矿业
HAINAN MINING

NISCO

FCT



Rooted in China, Connecting the World

Fosun was founded in 1992 by graduates of Fudan University. Since its establishment, Fosun has implemented its twin-driver strategy of "Industry Operations + Industrial Investment" to strengthen its foothold in various industries. Through continuous innovation, Fosun has achieved rapid development by capitalizing on the high-growth sectors that benefit from the momentum of China and the world's economic development.

1992

Founded with an initial investment of RMB38,000

1998

Fosun Pharma listed on China's A-share Market

2003

Nanjing Iron & Steel
Sinopharm Group

2010

Club Med
Henlius

2012

Pramerica Fosun Life Insurance
Peak Reinsurance
Starcastle Senior Living

2014

Fidelidade
Luz Saúde
Roc Oil

2016

Gland Pharma
Hauck & Aufhäuser
Wolverhampton
Wanderers
Babytree
AHAVA

2018

LANVIN
Wolford
Baihe Jiayuan
Songhelou
Fosun Tourism Group listed on HKEX

2020

DJULA
WEI
Jinhui Liquor
Shede Spirits

1994

Fosun Pharma Forte

2002

Yuyuan Inc.

2007

Hainan Mining Fosun International listed on HKEX (00656.HK)

2011

BFC

2013

Atlantis Sanya
Foshan Fosun Chancheng Hospital
Sisram Med

2015

Privatization of Club Med
Thomas Cook
Silver Cross

2017

Fosun United Health Insurance
Dongjia App

2019

FFT
Henlius listed on HKEX

2021

Sergio Rossi





Talents – The Most Valuable Asset of Fosun

A robust team of talents (talent bench) determines the scalability (breadth & depth) of the Company's future development

- **Our elite management team:** 110+ global partners, 220 industrial/line partners with regular rotation to involve in *each project, sector, and region*
- **GLOCAL:** *More than 10 overseas global partners coming from countries including Portugal, France, Germany, the United Kingdom, Japan, India, the United States, etc.*
- **Our talent development strategy:** *Attract people by **development**, appraise people over **performance**, train people through **works**, and unite people with **career opportunities***



FOSUN 复星

Business Overview





HEALTH

*Technology - Reshaping the Healthcare Sector,
Creating a Better World*

Medical Diagnostic and Treatment Technology

Fosun adopts a global R&D + diversified innovation model (investment, incubation, BD, etc.) to create high-value innovative products in the fields of pharmaceutical, devices, and diagnosis

Nearly 2,300

Number of R&D employees in 2020

247

Pipeline projects including new drugs under development, generic drugs, biosimilar and quality consistency evaluation of generic drugs

RMB4.0 billion+

R&D investment of Fosun Pharma in 2020

COVID-19 mRNA vaccine

Jointly developed with BioNTech

China's first CART-T cell therapy

Fosun Kite Axicabtagene Ciloleucel (FKC876)

First biosimilar approved in both China and Europe

汉曲优® (Zercepac®)

First biosimilar approved to commercialize in China

汉利康® (Hanlikang)

Gland Pharma

Successfully listed in India in 2020

FOSUN PHARMA
复星医药

 **Henlius**
上海复宏汉霖生物技术股份有限公司

 **复星杏脉**
FOSUN AITROX

 **GLAND**

FOSUN DIAGNOSTICS
复星诊断

FOSUN Kite
— 复星凯特生物 —

 **sisram**
medical

Health Services

Integrate “medical and health insurance” to create a one-stop healthcare management platform for all aspects of life

Nearly 9,000

Sinopharm retail pharmacies in China

4,610


Medical beds in holding members' hospitals

35%

Insurance premium growth rate of Fosun United Health Insurance

**Ranked No. 1 of China's non-public hospitals
in terms of competitiveness**

Foshan Fosun Chancheng Hospital





Health Products

Focusing on key groups to develop maternal and child consumer goods, health platform, healthy food, creating product + consumer traffic portal

91.2 million

Babytree's monthly average active users

21.8 million

Babytree's monthly active users (MAU)


4.8 million

Boohee Health's annual active users

50.0 million+

Number of registered users of Boohee Health





HAPPINESS

Targeting family customers, focusing on contents, models, and products, and connecting online platforms with offline scenarios

Jewelry and Fashion

Towards a brighter life, creating an matrix of global jewelry and fashion brands of Fosun

3,468
Yuyuan jewelry and fashion chain stores and points-of-sale

A well-known skincare brand licensed by the Israeli government to mine raw materials at the Dead Sea
AHAVA

LANVIN
PARIS

AHAVA
ELEMENTAL BEAUTY FROM THE DEAD SEA



老庙



DJULA
JOAILLERIE / PARIS

SEA-GULL
海鷗表

上海
SHANGHAI



Lanvin fashion show at Yuyuan Garden



Laomiao Gold Yuyuan flagship store



AHAVA 24K gold mineral mud mask



Opening of the first DJULA store in China



Food and Beverage

Embracing time-honored brands to offer exquisite food to family customers worldwide

“The King’s menu”

Lu Bo Lang served two leaders of the Cambodian royal family

30

Songhelou noodle chain restaurants



Entertainment

Centered around sports, e-sports, film and television, and games to create a diversified entertainment experience of Fosun



C-end entrance

Baihe Jiayuan



東家·守藝人
謹傳承成為潮流

10,000+

Dongjia's craftsmen



RMB5.4 billion

Box office revenue of movie
'Hi, Mom'



144 years
Wolverhampton
Wanderers'
history



Tourism

Building the new lifestyle of “Everyday is **Foliday**” and infusing evolving concepts of tourism and leisure into everyday living

60+
Club Med
resorts in the world


ATLANTIS
SANYA
三亚·亚特兰蒂斯

~5 million visits
Atlantis Sanya's
average annual
customer flow

Club Med 
全球度假村，一价享精彩

180 years
Since Thomas Cook's
establishment

 **Thomas Cook**
托迈酷客

Club Med 
在这里，精彩你

 **HOLIDAY TOWN**
假日城
丽江地中海国际度假区



HAUCK & AUFGÄUSER

PRIVATE BANKERS SINCE 1858

WEALTH

Insurance + financial resources and asset management capabilities mutually empower each other to create a closed loop wealth ecosystem

Insurance

Globalization to foster steady development

RMB50 billion

Premium

RMB250 billion+

Investable assets

27.4%

Fidelidade insurance business's market share in Portugal

13.4%

La Positiva's total market share ranked third in the Peruvian insurance market

PeakRe >



FIDELIDADE
SEGUROS DESDE 1808

La Positiva
Seguros

FOSUN HEALTH
复星联合健康保险



Investment

Industrial investment + financial investment as a twin-driver to empower health, happiness, wealth and intelligent manufacturing in every aspect of life

EUR181.3 billion

Assets under Hauck & Aufhäuser's management/custody

15.5% Growth

Hauck & Aufhäuser's asset management scale

R\$19.7 billion

Assets under Guide's management

130,000

Number of Guide's personal customers

FOSUN CAPITAL
复星创富

复星
锐正 **FOSUN RZ CAPITAL**

Top 30 Best China's Private Equity Investment Institutions in 2020

Fosun Capital



HAUCK & AUFHÄUSER
PRIVATBANK SEIT 1796



Two IPOs in the US

Invested companies under Fosun RZ Capital

FOSUN HANI
复星恒利



RIO BRAVO

Top 50 Best Chinese Venture Capital Institutions in 2020

Fosun RZ Capital

Fosun Hive

People and industry-oriented to build a global hive city



IDÉRA
CAPITAL MANAGEMENT

RMB64.35 billion
Fosun Hive's onshore
assets under management

US\$12.0 billion
Fosun Hive's offshore
assets under management



BFC THE BUND
FINANCE CENTER
外滩金融中心



28 LIBERTY

FORTE 复地
汇世界全生活

GULTE 高地



A wide-angle photograph of a modern industrial factory floor. Several yellow and orange robotic arms are mounted on light blue cylindrical bases. The robots are arranged in a line, with some in the foreground and others receding into the background. The floor is marked with orange and grey stripes. The ceiling is high with a large skylight and industrial lighting fixtures. The overall scene depicts a highly automated manufacturing environment.

INTELLIGENT MANUFACTURING

*Global deployment of digital intelligence technology
to empower industrial manufacturing*

Implementation of the C2M model and leverage on big data, artificial intelligence, and IoT, to promote intelligent manufacturing and create a flexible digital supply chain

FFT - one of the world's largest suppliers of intelligent manufacturing solutions for the automotive industry

JEVE - a leading domestic soft pack lithium battery company



Nanjing Iron & Steel – a super large iron and steel joint enterprise in China and one of the 18 key steel enterprises in the national's strategic layout



Hangzhou-Shaoxing-Taizhou Railway (Hangshaotai Railway)
- China's first privately held high speed rail project and one of the first batch of eight social capital investment railway demonstration projects in China




FOSUN 复星

Our Strategies




Fosun's Strategic Framework: Focus on Family Customers, Ecosystem Multiplier Effect + Innovation-Driven

FOSUN 复星




FC2M (Client to Maker) *FC2M ecosystem is formed around family needs, providing them the ultimate products and services*



Insurance (Finance) + Investment


FOSUN 复星

- Enhance product capabilities, improve the underwriting capabilities, and continue to expand the scale of insurance investable funds
- Optimize asset allocation and strengthen investment capabilities



Continue to strengthen the presence in the global insurance sector

Enhance the global investment footprint with profound industry operations



- Continue to look for high-quality investment targets that align with the concept of "Combining China's Growth Momentum with Global Resources"
- Focus on high-quality companies in the core strategic direction of wealth, health, happiness, and intelligent manufacturing
- Invest in outstanding companies that conform to the C2M concept and generate multiplier synergy



Innovation-driven

Create a multi-dimensional innovation system through **proprietary R&D, investment incubation, patents and cooperative introduction of innovative products**. Focus on **family scenario**, take the lead in the global innovation field, create good products of Fosun with high competitiveness.



Health Technology



First self-developed biosimilar approved for marketing in China
First China-developed monoclonal antibody biosimilar to enter the European market



World's leading CAR-T cellular immunotherapy treatment against cancer



Cooperate with world's leading mRNA tech company in developing COVID-19 vaccine



Creative Design



Leading domestic handmade craft platform



France's oldest haute couture house that remains active



FOSUN 复星



Smart Technology / Intelligent Manufacturing



Leading AI medical technology company



MIT's intelligent manufacturing demonstration point



World's leading provider of flexible supply chain solutions



Profound “Industry Operations + Industrial Investment” Twin-driver

Fosun has profound industry operations capabilities, yet investment is also in Fosun’s genes. Its long-established industry operations capabilities have enabled Fosun to grasp investment opportunities around the world. Fosun also possesses **industrial empowering capabilities** and drives **multiplier growth through the synergies** between industries within the ecosystem.

1

Selection

Innovation Barrier
 Market Growth Potential
 Globalization Potential
 Winning Potential for Fosun
 Aligning Core Businesses’
 Development Track

2

Entry

M&A
 VC Investment
 Joint Venture
 Franchise
 Industrial Hive

3

Optimization

Strategic Planning
 Structure Optimization
 Talent and Incentive Mechanism
 Investment in R&D and Innovation
 Leaning Operation and Procedure

4

Synergy


Supply Chain
 Marketing
 Investment
 Capital
 Smart Technology




Building FES, “Industry Operations + Industrial Investment” Twin-driver

FES: Fosun Entrepreneurship/Ecosystem System

Main Sectors of FES



- FES is a system of operation + investment management
- FES is the extract of the best practice of Fosun operations and management, empowering Fosun companies globally
- FES serves industrial investment and supports the growth of core businesses
- FES aims at increasing clients’ satisfaction, developing co-entrepreneurship, enhancing Fosun ecosystem synergy, and driving multiplier growth



Glocalization: Global + Local Twin-driver

Global Footprints

Global Businesses

Global Innovation

Global Talents

- Profound industry operations in more than 20 countries and regions across five continents in the world
- Over 40% of the revenue in 2020 generated from overseas countries or regions
- Set up “Shanghai-Silicon Valley” global innovative twin headquarters, forming an interactive and integrated pharmaceutical R&D system in China, the United States, India, etc.
- More than 10 overseas partners among over 110 global partners

France
Club Med
LANVIN
St Hubert
DJULA
TRIDEM
PAREF

U.K.
Silver Cross
Wolverhampton Wanderers
Thomas Cook
Resolution Property

Germany
Tom Tailor
H&A
NAGA
Koller
FFT

Israel
Sisram Med
AHAVA

Belgium
IGI

Austria
Wolford

Russia
Fosun Eurasia

China
Fosun Pharma
Henlius
Sinopharm
Starcastle Senior Living
Yuyuan Inc.
Laomiao
Shede Spirits
Jinhui Liquor
Fosun Tourism Group
Atlantis Sanya
BFC
Peak Reinsurance
Nanjing Iron & Steel
Hainan Mining
Fosun Hani
Pramerica Fosun Life Insurance

U.S.
St.John
Studio 8
WEI
AmeriTrust
28 Liberty
Fourtrees
Everest

Peru
La Positiva

Brazil
Rio Bravo
Guide


Portugal
Fidelidade
Luz Saúde
Millennium BCP
Fosun Hive Iberia

Italy
Caruso
The Medelan
Sergio Rossi

Singapore
Fosun Hive
Capital
Management

India
Gland Pharma
Delhivery
AHÜJA

Japan
Tomamu
The Court
IDERA
MIRAI
Australia
Roc Oil



FOSUN 复星



Our Pursuit




■ Fosun Foundation Art Center

- 19 Art exhibitions
- 223 Public education activities
- **Over one million** visitors

■ Tai Chi Anti-Parkinson's Disease

- Set up 9 charitable centers in cities such as Shanghai and Dongyang to host "Tai Chi Anti-Parkinson's Disease"
- Organized thousands charitable courses of "Tai Chi Anti-Parkinson's Disease", benefited nearly 400 patients to improve symptoms of Parkinson's disease since 2015

■ Rural Doctors Poverty Alleviation Program




■ Protecting

Global Youth Start-up Acceleration Program

- Received **887** applications from **42** countries in four years
- **12** awarded programs entered incubation in Fosun
- Won **three international awards** in recognition of its corporate social responsibility
- **33** closely cooperated start-up projects
- **Five** companies signed commercial contracts

■ Fight Against Malaria in Africa

- Fosun Pharma supplied over **200 million** artesunate injections to the international market, benefited over **40 million** patients with severe malaria, most of whom were under five



ESG Sustainable Development

FOSUN 复星

MSCI

MSCI ESG RATINGS

A

CCC B BB BBB **A** AA AAA

Hang Seng Index

Hang Seng Corporate Sustainability Index Series

A

Fosun International selected as a constituent stock of the Hang Seng Corporate Sustainability Benchmark Index (top 20%) and the Hang Seng ESG 50 Index (top 50 large-to-mid cap)

International Organizations¹

United Nations Global Compact

PSI Principles for Sustainable Insurance

FINANCE UNEP INITIATIVE

PRI Principles for Responsible Investment

Sustainable Investment Forum Europe

Key Performance	Environmental	Social	Corporate Governance
	 <p>2020 Carbon Intensity 130.7 ton/million RMB income</p>	 <p>Accumulated Donation by Fosun Foundation > 600 million RMB (2020 donation 208m RMB)</p>	 <p>2020 Female Employees 47.2%</p>
	 <p>2020 Energy Intensity 324.4 MWh/million RMB income</p>	 <p>Total Beneficiaries of Fosun Foundation > 22 million²</p>	 <p>Responsible Global Tax Citizen Fosun Group Tax Guidelines</p>
	 <p>2020 Water Consumption 292.3 ton/million RMB income</p>	 <p>Total Investment in Clean Technology > 5 billion RMB</p>	 <p>Global Partners > 110</p>

1: Fosun and/or member companies are members of the mentioned organizations.

2: Data as of end of 2019. Beneficiaries are too many to be counted afterwards.

Fight Against COVID-19: Global Capability, Global Responsibility

Phase 1: Combat the Outbreak in China

(From 24 January 2020 to 1 March 2020)


- In early 2020 when COVID-19 broke out, Wuhan was in lockdown and supplies were scarce, Fosun swiftly initiated the Global Medical Supplies Deployment Plan. Fosun immediately deployed medical supplies including **50,000** protective suits from Germany to Wuhan in only **4 days**, becoming the first large batch of medical supplies delivered to China.
- Fosun leveraged its strong global resource allocation capabilities to deploy medical supplies including protective suits, masks, ventilators from **23 countries**, which provided strong support for China's fight against the pandemic
- With the pandemic surging globally, Fosun proactively supported the overseas countries in fighting against COVID-19 and also actively facilitated the **R&D and launch of the COVID-19 mRNA vaccines**



Phase 2: Support the Global Battle

(From 1 March 2020 – present)

- Carried forward the spirit of humanitarianism to support the global fight against COVID-19, deployed over **147 million** supplies including nucleic acid test kits, ventilators, masks, protective suits, and protective gloves etc.; supported **30+** countries with its self-developed COVID-19 nucleic acid test kit, which was approved by **CNMPA, EU and FDA**
- Cooperated with **BioNTech to jointly develop COVID-19 vaccines based on its mRNA technology platform**. The vaccine has received approvals to commercialize in **Hong Kong SAR and Macau SAR**, and first batch of vaccines have arrived in Taiwan Region in early September
- Helped India to fight the pandemic, provided **20,000** oxygen concentrators and **100,000** KN95 masks



Guarding Rural Doctors *Delivering hope to impoverished people in rural areas*

Rural doctors are one of the critical forces to realize the goal of common prosperity. Since December 2017, under the instruction of the National Health Commission Poverty Relief Office, Fosun Foundation, together with China Population Welfare Foundation, etc., has initiated the Rural Doctors Poverty Alleviation Program (“Rural Doctors Program”). The program empowers millions of rural doctors who are working in the frontlines, with a view to accelerating the realization of “Chinese Dream” – Chinese people enjoy healthier lives.

4 years

219 on-site workers

Covered **16** provinces, cities, autonomous regions across the country

72 key national poverty-stricken counties

(including 13 counties in Three Regions and Three Prefectures in extreme poverty, which have all lifted out of poverty)

Assisted **12,545** administrative village clinics

Guarded **23,956** rural doctors

Benefited **3 million** grass-root families

Awards in 2021: National Advanced Collective in Poverty Alleviation Award, China Charity Award



Data as of 30 September 2021

Fight Against Malaria in Africa *Helping achieve “malaria-free world”*

2亿支!
2011-2021年，复星医药为全球提供注射用青蒿琥酯逾2亿支

WHO官网显示，疟疾患者中，撒哈拉以南非洲5岁以下儿童占全球疟疾死亡人数的三分之二。每两分钟，世界上就有一个孩子死于疟疾。历时10年，复星医药儿童用青蒿琥酯让5岁以下非洲儿童不再“谈疟色变”

ZERO MALARIA FOSUN 复星医药 FOSUN PHARMA 复星医药 FOSUN LIVE 复星医药

共建无疟疾世界 实现零疟疾目标 | 4.25 世界防治疟疾日

4000万!
2011年以来，注射用青蒿琥酯在非洲挽救超4000万名重症疟疾患者的生命

一名非洲少年画出心目中的“无疟疾世界”。随着全球公共卫生事业的发展，以及复星医药青蒿琥酯为代表的抗疟药在世界各地推广，2000-2019年间，本土疟疾病例少于100例（这是一个代表消除疟疾目标且可行的有力指标）的国家和地区从6个增加到27个。复星特为构建人类卫生健康共同体不懈奋斗，愿这青少年，将成为见证“疟疾绝迹的一代”

ZERO MALARIA FOSUN 复星医药 FOSUN PHARMA 复星医药 FOSUN LIVE 复星医药

共建无疟疾世界 实现零疟疾目标 | 4.25 世界防治疟疾日



“We will join forces and work together with malaria scientists as well as healthcare professionals to continue to carry out malaria education projects for the public, to leverage people's awareness of malaria prevention. We will actively participate in public health improvement and make steady efforts to build a malaria-free world.”

——Guo Guangchang

200 million+

The number of artesunate injections that Fosun Pharma supplied to the global market from 2011 to 2021

40 million+

*The number of severe malaria patients that **Artesun®**, an innovative drug with independent intellectual property rights for injection has saved, most of the patients were children under 5 years old in Africa*



Better Protection For Families

mRNA COVID-19 Vaccine

Global Joint Development Efforts

Continuously ensures the supply of vaccines for the Greater China region in the hope of building a herd immunity in China

As a vaccine representing global joint efforts, the Fosun/BioNTech mRNA COVID-19 vaccine demonstrates the wisdom of Chinese scientific research and the innovative capabilities of global pharmaceutical companies, which is a great example of Sino-German cooperation to promote the transformation of scientific R&D achievements.


Leveraging its pharmaceutical advantages and global R&D deployment, Fosun developed the mRNA COVID-19 vaccine through global collaboration, ensured state-of-the-art mRNA vaccine technology and other vaccine technologies to establish a vaccine R&D matrix in China, bringing hope to the global battle against COVID-19 pandemic.



On 24 November 2020, phase II clinical trial of mRNA COVID-19 vaccine BNT162b2 commenced in Chinese Mainland



On 27 February 2021, first batch of Fosun/BioNTech mRNA COVID-19 vaccine COMIRNATY® arrived in Hong Kong SAR from Germany





*Follow us on WeChat
to learn more about
the latest news of Fosun*

